0001437749-19-024347.txt : 20191212 0001437749-19-024347.hdr.sgml : 20191212 20191212202707 ACCESSION NUMBER: 0001437749-19-024347 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191210 FILED AS OF DATE: 20191212 DATE AS OF CHANGE: 20191212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rice Michael CENTRAL INDEX KEY: 0001389512 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 191283088 MAIL ADDRESS: STREET 1: C/O BIOLIFE SOLUTIONS, INC. STREET 2: 171 FRONT STREET CITY: OWEGO STATE: NY ZIP: 13827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 rdgdoc.xml FORM 4 X0306 4 2019-12-10 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001389512 Rice Michael C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 1 President & CEO Common Stock 2019-12-10 5 G 0 7000 0 D 168014 D Common Stock 2019-12-10 4 M 0 10000 1.12 A 178014 D Common Stock 2019-12-10 4 S 0 10000 15.37 D 168014 D Common Stock 2019-12-12 4 M 0 10247 1.12 A 178261 D Common Stock 2019-12-12 4 S 0 10247 15.11 D 168014 D Employee Stock Option 1.12 2019-12-10 4 M 0 10000 0 D 2011-02-25 2021-02-25 Common Stock 10000 10247 D Employee Stock Option 1.12 2019-12-12 4 M 0 10247 0 D 2011-02-25 2021-02-25 Common Stock 10247 0 D This transaction represents a charitable donation to a third party. No value was received for the gifted shares. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.35 to $15.41, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.18, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The reporting person's Form 4 filed on November 14, 2019 reported a remainder of 10,247 derivative securities when in fact the remainder was 20,247 derivative securities beneficially owned by the reporting person. /s/ Michael Rice 2019-12-12